OCULUS study: Virtual reality-based education in daily clinical practice.
Administration, Oral
Aged
Anticoagulants
/ administration & dosage
Atrial Fibrillation
/ complications
Female
Health Knowledge, Attitudes, Practice
Health Literacy
Humans
Male
Middle Aged
Mobile Applications
Patient Education as Topic
/ methods
Prospective Studies
Risk Assessment
Risk Factors
Smart Glasses
Smartphone
Stroke
/ diagnosis
Time Factors
Treatment Outcome
Virtual Reality
atrial fibrillation
education
stroke
three-dimensional movie
virtual reality
Journal
Cardiology journal
ISSN: 1898-018X
Titre abrégé: Cardiol J
Pays: Poland
ID NLM: 101392712
Informations de publication
Date de publication:
2019
2019
Historique:
received:
13
11
2017
accepted:
14
12
2017
pubmed:
4
1
2018
medline:
6
5
2020
entrez:
4
1
2018
Statut:
ppublish
Résumé
Atrial fibrillation (AF) is associated with high risk of stroke and other thromboembolic complications. The OCULUS study aimed to evaluate the effectiveness of the three-dimensional (3D) movie in teaching patients about the consequences of AF and pharmacological stroke prevention. The study was based on a questionnaire and included 100 consecutive patients (38% women, 62% with AF history). Using the oculus glasses and a smartphone, a 3D movie describing the risk of stroke in AF was shown. Similar questions were asked immediately after, 1 week and 1 year after the projection. Before the projection 22/100 (22.0%) declared stroke a consequence of AF, while immediately after 83/100 (83.0%) (p < 0.0001) patients declared this consequence. Seven days after, stroke as AF consequence was chosen by 74/94 (78.7%) vs. 22/94 (23.4%) when compared to the baseline knowledge; p < 0.0001, a similar trend was also observed in 1-year follow-up (64/90 [71.1%] vs. 21/90 [23.3%]; p < 0.0001). Before the projection 88.3% (83/94) patients responded, that drugs may reduce the risk of stroke, and after 1 week the number of patients increased to (94/94 [100%]; p = 0.001). After 1 year 87/90 (96.7%) answered that drugs may diminish the risk of stroke (p = 0.02 in comparison to the baseline survey 78/90 [86.7%]). Use of oral anticoagulation to reduce the risk of stroke was initially chosen by 66/94 (70.2%), by 90/94 (95.7%; p < 0.0001) 7 days after and by 83/90 (92.2%; p < 0.0001) 1 year after. 3D movie is an effective tool in transferring knowledge about the consequences of AF and the pivotal role of oral anticoagulation in stroke prevention. ClinicalTrials.gov, NCT03104231. Registered on 28 March 2017.
Sections du résumé
BACKGROUND
Atrial fibrillation (AF) is associated with high risk of stroke and other thromboembolic complications. The OCULUS study aimed to evaluate the effectiveness of the three-dimensional (3D) movie in teaching patients about the consequences of AF and pharmacological stroke prevention.
METHODS
The study was based on a questionnaire and included 100 consecutive patients (38% women, 62% with AF history). Using the oculus glasses and a smartphone, a 3D movie describing the risk of stroke in AF was shown. Similar questions were asked immediately after, 1 week and 1 year after the projection.
RESULTS
Before the projection 22/100 (22.0%) declared stroke a consequence of AF, while immediately after 83/100 (83.0%) (p < 0.0001) patients declared this consequence. Seven days after, stroke as AF consequence was chosen by 74/94 (78.7%) vs. 22/94 (23.4%) when compared to the baseline knowledge; p < 0.0001, a similar trend was also observed in 1-year follow-up (64/90 [71.1%] vs. 21/90 [23.3%]; p < 0.0001). Before the projection 88.3% (83/94) patients responded, that drugs may reduce the risk of stroke, and after 1 week the number of patients increased to (94/94 [100%]; p = 0.001). After 1 year 87/90 (96.7%) answered that drugs may diminish the risk of stroke (p = 0.02 in comparison to the baseline survey 78/90 [86.7%]). Use of oral anticoagulation to reduce the risk of stroke was initially chosen by 66/94 (70.2%), by 90/94 (95.7%; p < 0.0001) 7 days after and by 83/90 (92.2%; p < 0.0001) 1 year after.
CONCLUSIONS
3D movie is an effective tool in transferring knowledge about the consequences of AF and the pivotal role of oral anticoagulation in stroke prevention.
TRIAL REGISTRATION
ClinicalTrials.gov, NCT03104231. Registered on 28 March 2017.
Identifiants
pubmed: 29297178
pii: VM/OJS/J/56095
doi: 10.5603/CJ.a2017.0154
pmc: PMC8086674
doi:
Substances chimiques
Anticoagulants
0
Banques de données
ClinicalTrials.gov
['NCT03104231']
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
260-264Références
Physiotherapy. 2017 Sep;103(3):245-258
pubmed: 28109566
Kardiol Pol. 2017;75(5):495-501
pubmed: 28281732
Pain Manag. 2011 Mar;1(2):147-157
pubmed: 21779307
Europace. 2015 Mar;17(3):468-72
pubmed: 25722478
Am J Otolaryngol. 2017 Mar - Apr;38(2):174-178
pubmed: 28089173
Stroke Res Treat. 2016;2016:6210508
pubmed: 28058130
J Alzheimers Dis. 2017;56(2):619-627
pubmed: 28035922
J Clin Periodontol. 2014 Jan;41(1):38-45
pubmed: 24111854
Europace. 2016 Jan;18(1):151-5
pubmed: 26462697
Kardiol Pol. 2017;75(10):1056
pubmed: 29057443
Cardiol J. 2019;26(5):594-603
pubmed: 30566211
Europace. 2016 Mar;18(3):463-7
pubmed: 26899998
Rev Esp Cardiol (Engl Ed). 2017 Jan;70(1):50
pubmed: 28038729